MacroGenics reported $37.01M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Amgen USD 54.6B 17M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Biogen USD 6.56B 275.1M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Genmab DKK 148M 5M Jun/2025
Geron USD 121.99M 76K Dec/2025
Gilead Sciences USD 24.94B 5M Dec/2025
J&J USD 47.93B 2.14B Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Merck USD 49.34B 7.97B Dec/2025
Pfizer USD 63.73B 231M Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Xencor USD 187.75M 118.48M Dec/2025